MedTrace Logo

Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer

NCT00842491 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2015-05-19

No results posted yet for this study

Summary

The purpose of this study is to investigate whether endostar (recombinant human endostatin)with cisplatin and capecitabine (Xeloda) as 1st line treatment in the advanced gastric cancer is effective and safe.

Conditions

  • Advanced Gastric Cancer

Interventions

DRUG

endostar, cisplatin, capecitabine

Product 1: endostar Dosing schedule: 15mg daily dose, d1-14 Mode of administration: intravenously

DRUG

capecitabine

Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally

DRUG

cisplatin

Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously

Sponsors & Collaborators

  • Xiansheng Pharmaceutical Company

    collaborator UNKNOWN

  • Peking University

    lead OTHER

Principal Investigators

  • lin shen, MD · Peking University, School of oncology, Department of GI oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-04-30
Completion
2010-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00842491 on ClinicalTrials.gov